🔔 Last chance to take advantage of our anniversary sale! Join us in celebrating 15 years of supporting researchers with a minimum 15% discount on all orders of our custom ubiquitin proteasome reagents until 31 Aug. 💻 rb.gy/35clhh 📩 [email protected]

We’re delighted to be partnering with @AlleoLabs to accelerate DUB-focused drug discovery! This collaboration will combine Alleo’s AI-based platform with our expertise in the DUB space to advance DUB-focused preclinical programmes. ➡ tinyurl.com/283d7o5o

Next week, Hozefa Amijee and Rishi Shah will be at #BIOEurope,discussing how we are using our industry-leading platform to build a portfolio of novel DUB-targeting compounds to accelerate our partners’ programmes. Learn more: 💻ubiquigent.com 📩 [email protected]

#BIOEurope has kicked off, bringing together industry leaders to discuss the future of biotech. Our team have a busy week ahead, meeting with partners, customers, and potential investors to share insights into our novel approach to DUB-focused #drugdiscovery.📩[email protected]

We had a great time at #BIOEurope Autumn! 🍂 In case you missed us, there’s still time to schedule a meeting during the virtual partnering event on 12-13 November – contact us at [email protected] to find out more. #DrugDiscovery #DrugDevelopment #Pharma #Biotech #DUB

📢Ubiquigent launches DUBprofiler Open Access Initiative Many #DUB inhibitors in the public domain have inadequately characterised selectivity. To counter this, we're inviting scientists to submit non-proprietary compounds for characterisation at no cost: bit.ly/4f8GDOP

Interested in learning more about the potency & selectivity of your compounds? Join our DUBprofiler Open Access Initiative & submit non-proprietary DUB modulators for screening against our gold standard #assay before 31 Jan. 💻 bit.ly/4f8GDOP 📩 [email protected]

Last call to submit to our DUBprofiler Open Access Initiative! Submit your DUB inhibitors for screening - gain insights into your non-proprietary compounds’ potency & selectivity to ensure your research & #drugdiscovery programmes have a strong foundation: [email protected]

To all our valued customers, collaborators, partners and suppliers, we regret to inform you that Ubiquigent Limited is no longer providing access to high-quality, validated reagents or services to support your Ubiquitin Proteasome System (UPS) related research.

We are in the process of transferring the Ubiquigent brand to a new owner, who may, in due course, provide future support to UPS research worldwide. We wish you all well with your future research and scientific endeavours.